Encouragingly, a retrospective study discovered an improved anti-leukemic effect of DLI after administration of G-CSF compared to conventional donor lymphocyte infusion (DLI) in patients who relapsed after allo-HCT, given that it was enriched in MDSCs and did not increase the cumulative GVHD incidence [126]. The gene discussed is CSF3; the disease is graft versus host disease.